c-Myc RNA-targeting small molecule / Wayfinder Biosciences - LARVOL DELTA

Potent, orally bioavailable small molecules that inhibit c-Myc translation and suppress tumor growth in vivo (AACR 2026) - "Our promising in vivo data, coupled with sustained oral exposure and favorable tolerability, highlight the potential of this modality to overcome long-standing barriers in MYC drug discovery. Ongoing xenograft and mechanistic studies are expected to further expand the clinical opportunities for treating MYC-driven solid and hematologic cancers."

Preclinical • Hematological Malignancies • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor • MYC